How should Candida non‑albicans isolated from urine be interpreted and managed, including indications for treatment and recommended antifungal therapy?

Management of Candida Non-Albicans in Urine

Initial Clinical Decision: Treat or Observe?

Most patients with Candida non-albicans isolated from urine do not require antifungal treatment, as candiduria almost always represents benign colonization rather than infection and treatment does not reduce mortality or improve outcomes. 1

Asymptomatic Patients – Observation Only

• Asymptomatic candiduria should not be treated in otherwise healthy individuals, diabetic patients without additional high-risk features, or elderly patients, as it represents colonization and provides no clinical benefit. 1
• Candiduria progresses to candidemia in less than 5% of cases, serving primarily as a marker of illness severity rather than a cause of morbidity. 1, 2
• Immediate removal of any indwelling urinary catheter resolves candiduria in approximately 50% of cases without antifungal therapy, making this the single most important intervention. 1, 2
• Discontinuation of unnecessary broad-spectrum antibiotics should be undertaken, as these are major risk factors for candiduria development. 1

High-Risk Asymptomatic Patients Requiring Treatment

Despite lack of symptoms, mandatory treatment is indicated for:

• Neutropenic patients with persistent unexplained fever and candiduria, due to heightened risk of disseminated candidiasis. 1, 2
• Very low-birth-weight neonates (< 1500 g), who have high propensity for invasive candidiasis. 1, 3
• Patients undergoing urologic procedures or instrumentation within several days, to prevent procedure-related candidemia. 1, 3
• Patients with urinary tract obstruction that cannot be promptly relieved, as obstruction sustains fungal persistence. 1

---

Treatment Regimens for Symptomatic Candiduria

Symptomatic Cystitis (Lower UTI)

For fluconazole-susceptible Candida non-albicans species, fluconazole 200 mg (3 mg/kg) orally once daily for 14 days is the first-line therapy, based on randomized controlled trial evidence demonstrating efficacy. 1, 2, 3

• Fluconazole achieves high urinary concentrations of active drug, ensuring effective pathogen eradication. 1, 2, 4
• Clinical indicators of symptomatic cystitis include dysuria, frequency, urgency, and suprapubic pain. 1

Symptomatic Pyelonephritis (Upper UTI)

For fluconazole-susceptible organisms, fluconazole 200–400 mg (3–6 mg/kg) orally once daily for 14 days is recommended, using the higher 400-mg dose when upper-tract involvement is confirmed. 1, 2, 3

• Suspect pyelonephritis when flank pain, fever > 38.3°C, or systemic manifestations develop. 1
• Obtain renal or bladder imaging (ultrasound or CT) if symptoms persist beyond 48–72 hours to exclude obstruction, fungal balls, or perinephric abscesses. 1

---

Management of Fluconazole-Resistant Non-Albicans Species

Candida glabrata (Often Fluconazole-Resistant)

C. glabrata frequently exhibits fluconazole resistance and requires alternative antifungal agents. 1, 2, 5

• For cystitis: Amphotericin B deoxycholate 0.3–0.6 mg/kg IV daily for 1–7 days or oral flucytosine 25 mg/kg four times daily for 7–10 days. 1, 3
• For pyelonephritis: Same amphotericin B regimen, with optional addition of oral flucytosine. 1
• Flucytosine monotherapy (25 mg/kg qid for 7–10 days) may be considered when amphotericin B is unsuitable, though this is a weaker recommendation. 1

Candida krusei (Intrinsically Fluconazole-Resistant)

C. krusei is universally resistant to fluconazole and requires amphotericin B deoxycholate 0.3–0.6 mg/kg IV daily for 1–7 days as the treatment of choice. 1, 3, 5

Refractory Fluconazole-Resistant Cystitis

• Bladder irrigation with amphotericin B deoxycholate (50 mg/L sterile water daily for 5 days) may be employed for refractory C. glabrata or C. krusei cystitis, though relapse rates exceed 80–90%. 1, 3
• This approach should be reserved only for cases where systemic therapy has failed. 3

---

Special Clinical Scenarios

Patients Undergoing Urologic Procedures

Fluconazole 400 mg (6 mg/kg) daily or amphotericin B deoxycholate 0.3–0.6 mg/kg daily should be administered for several days before and after the procedure. 1, 2, 3

Fungus Balls (Bezoars) or Obstructive Uropathy

• Surgical or endoscopic removal is mandatory in addition to systemic antifungal therapy; antifungal agents alone fail without drainage. 1, 3
• For patients with nephrostomy tubes, adjunctive irrigation with amphotericin B deoxycholate 25–50 mg diluted in 200–500 mL sterile water is recommended. 1

Neutropenic Patients or Very Low-Birth-Weight Neonates

Treat as candidemia to prevent dissemination: use echinocandin (caspofungin 70 mg loading then 50 mg daily, anidulafungin 200 mg loading then 100 mg daily, or micafungin 100 mg daily) or lipid formulation amphotericin B 3–5 mg/kg daily for 2 weeks after documented bloodstream clearance. 1

Male Patients with Candiduria

• Candiduria in males should not be automatically dismissed as colonization; evaluate for possible prostatitis if urinary symptoms develop. 1, 2
• For Candida prostatitis/epididymo-orchitis, fluconazole is the agent of choice, with dose and duration extrapolated from cystitis recommendations. 2

---

Critical Pitfalls to Avoid

Ineffective Antifungal Agents for Urinary Infections

Never use echinocandins (caspofungin, micafungin, anidulafungin), newer azoles (voriconazole, posaconazole), or lipid formulations of amphotericin B for Candida urinary tract infections, as they achieve inadequate urine concentrations and are ineffective for lower-tract infections. 1, 2, 3

Diagnostic Pitfalls

• Colony counts and pyuria are unreliable for distinguishing colonization from infection, especially in catheterized patients; do not rely on these parameters. 1, 3
• The presence of yeast on urinalysis is common in hospitalized patients but rarely indicates true infection requiring treatment. 1

Treatment Failures

• Always remove or replace indwelling catheters before or during treatment; failure to address this predisposing factor leads to treatment failure and relapse. 1, 3
• For recurrent candiduria after appropriate therapy, evaluate for underlying urologic abnormalities such as strictures, stones, prostatic disease, or persistent obstruction. 1

---

Species Distribution and Resistance Patterns

• Among non-albicans Candida species isolated from urine, C. glabrata (20.6%), C. tropicalis (10.3%), C. parapsilosis (7%), and C. krusei (3.4%) are the most common. 6
• In ICU settings, C. tropicalis may predominate (57.3%) among non-albicans species. 7
• Most non-albicans Candida isolates remain susceptible to amphotericin B, though fluconazole resistance is observed in 18.6% of C. tropicalis, 27.3% of C. albicans, and 50% of C. glabrata strains. 7
• Biofilm formation is more common in C. albicans (55.6%) than non-albicans species (28.3%), particularly on plastic devices, and may contribute to treatment resistance. 8